Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $65.00 price target on the stock.
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights [Yahoo! Finance]